Systemic Therapies for Metastatic Melanoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Advanced local and metastatic melanoma (Stage IIB+) requires systemic treatment.
• Current systemic therapies are broadly categorized into immunotherapies and targeted therapies.

Purpose of the Study:

• To summarize the main categories of systemic therapies for advanced melanoma.
• To describe the mechanisms of action for immunotherapies and targeted therapies.
• To highlight the common adverse effects associated with these treatments.

Main Methods:

• Literature review and synthesis of current knowledge on melanoma systemic therapies.
• Classification of treatments based on mechanism of action and target.
• Identification of common adverse events reported in clinical practice and studies.

Main Results:

• Immunotherapies enhance T-cell anti-tumor activity by inhibiting immune checkpoints.
• Targeted therapies, for BRAF V600-mutant melanoma, inhibit activated oncoproteins like BRAF and MEK.
• Common adverse effects involve cutaneous, gastrointestinal, and endocrine systems.

Conclusions:

• Systemic therapies offer crucial treatment options for advanced melanoma.
• Understanding treatment mechanisms and potential adverse effects is vital for patient management.
• Further research may focus on mitigating these adverse effects to improve patient outcomes.